Daxor Announces Sales To Three New Hospitals Furthering Expansion Of Its User Base
Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology today announces the expansion of blood volume analysis (BVA) in three new hospitals through new analyzer purchases, and the utilization of Daxor's ezBVA Lab service. These new acquisitions further fuel BVA sales growth and underscore its clinical relevance.
New client and services wins include:
- BVA analyzer purchase at a 735-bed non-profit, tertiary, research and academic medical center located in northern New Jersey.
- Daxor's ezBVA Lab service extended to a regional academic medical center, Level I adult trauma center in Ohio.
- Daxor's ezBVA Lab service extended to an academic, integrated health system located in South Carolina.
"Our sales and marketing teams have kicked off the new calendar year with great momentum, and these new account openings in the past two weeks are further evidence of the more rapid uptake of our diagnostic solutions," said Michael Feldschuh, Daxor's CEO and President. "We remain focused on commercialization - broadening our reach with new analyzer sales, while driving increased utilization within our current customer base, supported by our expanding ezBVA Lab service. The continued growth of our client base paves the way for further adoption of our next-generation systems set to launch in the near term."